IPO Timeline
Broker Results (T-2)
2022-08-30
Some brokers release in afternoon
Grey Market (T-1)
2022-08-31
Afternoon
HKEX Allotment (T-1)
2022-08-31
Evening
Registrar Allotment (T-1)
2022-08-31
Evening
Listing Day (T)
2022-09-01
First day of trading
Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 百奥赛图 |
|---|---|
| Other Market Stock Code | 688796 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 百奧賽圖(北京)醫藥科技股份有限公司 - B - H 股 |
|---|---|
| Stock Code | 02315 |
| Company Full Name | 百奧賽圖(北京)醫藥科技股份有限公司 - B - H 股 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事藥物開發業務，包括腫瘤學和自身免疫性疾病治療的研發、抗體開發；以及提供臨床前研究服務，包括基因編輯、臨床前藥理藥效評估及模式動物銷售。 |
| Listing Date | 2022-09-01 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市大興區大興生物醫藥產業基地寶參南街12號院 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.biocytogen.com.cn/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 25.22 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 71.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 54,878,720 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 26.0 |
|---|---|
| First Day Open | HK$ 26.3 |
| First Day Change | 3.09% |
| First Day Volume | 2302000.0 |
| First Day Turnover | 61043900.0 |
Use of Proceeds
| Use of Proceeds | 1、約329.8百萬港元（即所得款項凈額約70%）用于為我們核心產品的進一步臨床研發提供資金； 2、約70.7百萬港元（即所得款項凈額約15%）用于根據我們的千鼠萬抗計劃為抗體藥物發現及開發提供資金； 3、約47.1百萬港元（即所得款項凈額約10%）用于我們其他管線產品的臨床前及臨床開發； 4、約23.6百萬港元（即所得款項凈額約5%）將用作營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (4)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
中信里昂证券有限公司 CE AAB893
Joint Bookrunners (8)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
中信里昂证券有限公司 CE AAB893
交银国际证券有限公司 CE APJ121
富途证券国际（香港）有限公司 CE AZT137
华盛资本证券有限公司 CE AUL711
海通国际证券有限公司 CE AAF806
Joint Lead Managers (8)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
中信里昂证券有限公司 CE AAB893
交银国际证券有限公司 CE APJ121
富途证券国际（香港）有限公司 CE AZT137
华盛资本证券有限公司 CE AUL711
海通国际证券有限公司 CE AAF806
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | QuantumPharm Inc. | 76,820,120 HKD | — | 14.00% | — | 6 months | 2023-03-01 |
| 2 | 北京兴星股权投资合伙企业(有限合伙) | 39,191,880 HKD | — | 7.14% | — | 6 months | 2023-03-01 |
| 3 | 荣昌生物制药(烟台)股份有限公司 | 78,383,760 HKD | — | 14.28% | — | 6 months | 2023-03-01 |
| 4 | 三金国际股份有限公司 | 78,383,760 HKD | — | 14.28% | — | 6 months | 2023-03-01 |
| 5 | 维科(香港)经贸有限公司 | 117,588,250 HKD | — | 21.43% | — | 6 months | 2023-03-01 |
Directors & Management
| Chairman | 沈月雷 |
|---|---|
| Company Secretary | 王永亮;區慧晶 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 沈月雷及關連人士(23.5%);國家開發投資集團有限公司(18.39%);全國社會保障基金理事會(7.32%);Astral Eminent Limited(6.58%);中國人壽保險股份有限公司(5.93%) |
|---|
IPO Timeline
